INTRODUCTION
Shigella is the cause of bacillary dysentery, a severe inflammation of the colon, which has been estimated to kill about half a million people annually. 1 The bacteria invade the colonic mucosa and remain confined at this site, rarely invading into deeper tissues or into the blood. 2 Nevertheless, the bacteria do interact with the host innate immune system, as shown by the severe inflammatory reaction which may occur during infection.
Several attempts have been made to modulate the host immune response during bacterial infections; clinical trials have been carried out where septicemic patients have been treated by the i.v. administration of such diverse substances as a TNF-α-blocking antibody 3 or recombinant bactericidal/permeability-increasing protein (BPI). 4 Regarding shigellosis, it has been shown that i.v. infusion of the IL-1β receptor antagonist IL-1RA during experimental Shigella infection of rabbits resulted in diminished tissue destruction and bacterial invasion of the intestinal mucosa. 5 The aim of this study was to evaluate the effect of antibody-mediated blockade of CD14 6 during experimental Shigella infection of rabbits. CD14 is expressed on the surface of most monocytes/macrophages and polymorphonuclear granulocytes, and has been proposed to be a 'pattern recognition receptor'. 7 This group of receptors is believed to recognize molecules derived from micro-organisms and signal the presence of danger to the host. Previous studies have shown that primates that were given an anti-CD14 monoclonal antibody i.v. prior to LPS infusion were protected against the development of endotoxic shock. 8 Conversely, transgenic mice expressing human CD14 were found to be hypersensitive to LPS. 9 Furthermore, CD14 knock-out mice were shown to be insensitive to the noxious effects of systemically administered LPS, as well as more efficient in controlling the dissemination of an intraperitoneal Escherichia coli inoculum, compared to wild-type mice. 10 Most recently, it was shown that anti-CD14 monoclonal Shigella infections lead to severe inflammation associated with destruction of colonic mucosa. We assessed the effect of in vivo blockade of CD14 on the outcome of experimental Shigella infection in rabbits. A total of 17 rabbits were divided into two groups: 8 received a single i.v. dose of anti-rabbit CD14 monoclonal antibody prior to infection with an invasive Shigella flexneri strain; the remainder served as controls. The anti-CD14-treated rabbits exhibited more severe tissue destruction and a 50fold increase in bacterial invasion of the intestinal mucosa when compared to controls. Similar numbers of polymorphonuclear leukocytes were recruited to the intestinal mucosa in both groups despite the massive bacterial invasion seen in the CD14-blocked group. No statistically significant differences were seen in levels of IL-1β nor in the ratio of IL-1RA/IL-1β for either group. In contrast, higher quantities of TNF-α were observed in the CD14-blocked group. To conclude, anti-CD14 treatment had a detrimental effect on the capacity of Shigella-infected animals to clear the infection. antibody protected rabbits even when administered after several doses of LPS in a multi-dosage model. 11
MATERIALS AND METHODS

Bacteria
Two Shigella strains were used: strain M90T, Shigella flexneri serotype 5a, previously isolated from a patient suffering from dysentery, and its isogenic, non-invasive mutant, BS176. 12 
Experimental Shigella infection of rabbits
Anesthetized New Zealand White rabbits received 5 mg/kg (15 mg in total) of a murine monoclonal IgG2a antibody directed against rabbit CD14 intravenously (clone 1116 1a6); 11 control rabbits were given either the same volume of saline, nothing or the same quantity (5 mg/kg) of a nonrelated murine monoclonal of the same isotype (w6/32). 11 Next, an abdominal midline incision was made and between 6 and 8 small intestinal loops created, into which 5 x 10 9 bacteria were injected. Eight hours later, the rabbits were sacrificed and intestinal biopsies were collected.
Immunohistological analyses
Intestinal tissue sections fixed in zinc salt solution were used. Endogenous peroxidase activity was quenched by immersing the slides in methanol containing 0.3% H 2 O 2 . Sections were incubated in a commercial blocking agent prior to the addition of primary antibodies: murine mAb anti-LPS of Sh. flexneri 5a (6 µg/ml; A. Phalipon, Unité PMM, Institut Pasteur, Paris, France) and polyclonal goat anti-rabbit bactericidal/permeability-increasing protein (BPI; 1:4000), the latter was a kind gift from Dr Jerold Weiss (New York University School of Medicine, NY, USA). Slides were washed before incubation with the secondary antibody, either biotinylated goat anti-mouse (E0433, Dako, Denmark) or biotinylated rabbit anti-goat (E0466, Dako). Slides were again washed, followed by the addition of streptavidin-horseradish peroxidase conjugate (Dako). Next, a tyramide signal amplification step (DuPont NEN) was done according to the instructions of the manufacturer. The color reaction was developed by the addition of H 2 O 2 and amino-ethyl-carbazole (AEC, Sigma).
Cytokine assays
Intestinal biopsies were put into a solution of protease inhibitors as previously described, 13 homogenized, and ultracentrifuged at 100,000 g. The supernatants were collected and stored at -80°C until assayed for cytokine quantities. A sandwich ELISA was used for the detection of IL-1β and IL-1RA, as previously described. 14 Supernatants were also assayed for TNF-α bioactivity using the TNF-α-sensitive murine fibrosarcoma cell line WEHI 164, clone 13, as previously described. 15 
RESULTS
Localization of CD14 in the normal rabbit intestine
In the normal rabbit intestine, there was little or no staining of the mucosa, whereas strongly CD14-positive cells were prominent in the submucosa. As expected, these cells had the morphology of macrophages/monocytes and polymorphonuclear granulocytes (not shown). We verified that the anti-CD14 antibody we planned to use in the blocking experiments did bind CD14-expressing cells in the intestine after i.v. injection by incubating the intestinal sections with the biotinylated goat anti-mouse antibody we normally used as secondary antibody.
Tissue destruction in CD14-blocked rabbits exposed to invasive Shigella
The next question to be addressed was whether there was a difference in the degree of tissue destruction caused by the invasive Shigella strain M90T in the intestinal mucosa of rabbits that had been treated with the anti-CD14 antibody compared to the control rabbits. Tissue destruction was assessed by measuring the height of intestinal villi. The geometric mean height of villi in CD14-blocked rabbits incubated with invasive Shigella was 145 µm, and the corresponding value for control rabbits was 294 µm. Thus, there was a statistically significant, 2.2-fold reduction in villus height in CD14-blocked rabbits compared to controls.
Upon macroscopic examination of the intestinal mucosa of rabbit intestinal loops incubated with the invasive Shigella strain, we noted that there was a trend toward hemorrhage being more frequent among CD14-blocked rabbits compared with controls. No hemorrhage was seen in loops exposed to the non-invasive Shigella strain BS176 in either of the two groups of rabbits. To examine this further, hematoxylin-eosin stained intestinal sections derived from CD14-blocked or non-blocked rabbits, incubated with the invasive strain were read blinded and the incidence of hemorrhage in the two groups of rabbits was assessed. It was found that 6/8 CD14-blocked rabbits versus 2/9 of the control rabbits developed hemorrhages upon infection with invasive Shigella, a difference which was not quite significant in Fisher's exact test (P = 0.057).
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Bacterial invasion of the intestinal mucosa of CD14blocked rabbits
Next, we examined the degree of bacterial invasion of the intestinal mucosa of CD14-blocked versus control rabbits incubated with the invasive Shigella strain. We used an immunohistochemical procedure in which the intestinal sections were incubated with a monoclonal antibody directed against the LPS of the Shigella strain. By using image analysis techniques, we calculated the percentage of mucosal surface that had been invaded by Shigella in CD14-blocked and control rabbits. The geometric mean mucosal area covered by the invasive strain was 4.2% in CD14-blocked rabbits, compared to only 0.079% in control rabbits. Thus, there was a 50-fold higher degree of bacterial invasion in the CD14-blocked rabbits (P = 0.011).
Effect of CD14-blockade on migration of PMNs to infectious foci
We sought to determine how anti-rabbit CD14 treatment affected recruitment of polymorphonuclear granulocytes (PMNs) to the intestinal mucosa. We counted the number of polymorphonuclear granulocytes in the intestinal mucosa in sections stained with Sirius red. There were no differences with respect to the numbers of PMNs recruited to the intestinal mucosa by Shigella infection, when comparing anti-CD14-treated rabbits and control rabbits.
Effect of CD14-blockade on the capacity of phagocytic cells to respond to LPS by the production of cytokines
The next hypothesis tested was whether blocking CD14 in vivo might affect the capacity of intestinal phagocytic cells to produce pro-inflammatory cytokines, such as IL-1 and TNF-α. No statistically significant levels were seen in the gut of the two groups of animals regarding either IL-1β or the ratio of IL-1RA/IL-1β (Table 1) . However, TNF-α levels were almost 20-fold higher in the CD14-blocked rabbits, and this difference was statistically significant ( Table 1) .
Effect of CD14-blockade on the capacity of phagocytic cells to degranulate in response to invasive bacteria
In order to evaluate whether there was a difference in the capacity of phagocytic CD14-bearing cells to degranulate in CD14-blocked versus non-blocked animals, we studied two components of the granules of phagocytic cells: myeloperoxidase (found in monocytes/macrophages and PMNs), and bactericidal/permeability-increasing protein (BPI; only found in PMNs). Although the myeloperoxidase activity was somewhat lower among the CD14blocked rabbits (geometric mean = 60 x 10 3 PMNs/mg tissue protein) compared to control rabbits (97 x 10 3 PMNs/mg tissue protein), this difference was not statistically significant. The capacity of PMNs to release their contents of BPI was evaluated using immunohistochemical staining. The staining pattern of BPI varied greatly in intestinal loops incubated with invasive Shigella regardless of whether they were derived from CD14-blocked or control rabbits. Nevertheless, a general feature was a 'gradient stain'-type pattern, in which PMNs far from the infectious foci (e.g. in the basal mucosa and submucosa) stained strongly, and PMNs closely associated to the infectious foci stained weakly or not at all. We could see no diminished or altered capacity of PMNs from CD14-blocked rabbits to degranulate in vivo compared to controls, when exposed to invasive Shigella (Fig. 1) .
DISCUSSION
This study demonstrates that blockade of CD14 prior to experimental Shigella infection of rabbits results in aggravated disease, reflected by enhanced bacterial invasion and tissue destruction. In order to elucidate the mechanisms by which inhibition of CD14 could weaken the host defense against a bacterial intestinal infection, it was necessary to determine the localization of CD14 in the rabbit intestine. We documented that CD14 is primarily confined to submucosal monocytes/macrophages and PMNs in the normal rabbit. This tissue distribution is essentially the same as that seen in humans, where the macrophages of the normal (non-inflamed) small intestine are negative for CD14. 16 In contrast, upon bacterial invasion of the intestinal mucosa, CD14-positive cells emigrated into the mucosa.
An increased frequency of hemorrhages was noted in the CD14-blocked rabbits exposed to invasive Shigella. Histopathological studies of the rectal mucosa of patients suffering from shigellosis have revealed that extensive vascular lesions are occasionally a feature of the disease. 17 Two recent studies have documented the importance of LPS-initiated host defense mechanisms in experimental bacterial infections of mice. Cross and co-workers showed that genetically LPS-hyporesponsive mice were 10,000 times more susceptible to lethal infection with a K1-encapsulated E. coli strain than normal, LPS-responsive mice. 18 The lower LD 50 dose in the LPS-hyporesponsive mice was mainly due to poor activation of monocytes/macrophages. 18 Another recent study has shown that mice deficient in the LPS-binding protein (LBP) had reduced capacity to combat an intraperitoneal inoculum of Salmonella typhimurium compared to wildtype mice. 19 These previous studies as well as those described herein comprise a body of data that emphasizes the importance of LPS-signaling in initiating host defense mechanisms against Gram-negative bacterial infections.
Our results may appear inconsistent with earlier studies which demonstrated that animals lacking CD14 or treated with a CD14-specific monoclonal antibody were protected against endotoxin-mediated shock. 8, 10 These divergent results are probably due to the fact that those earlier studies employed purified LPS or bacteria which were administered systemically, whereas we used live bacteria that were deposited on a mucosal surface. Hence, the aforementioned studies employed models that mimic septic shock, while the present study examined the outcome of CD14 blockade on a local, invasive bacterial infection. Thus, it may very well be that blocking the LPS receptor CD14 may be beneficial to the host during septicemia/septic shock, but deleterious during a locally invasive bacterial infection.
A pathogenic mechanism of invasive Shigella is the induction of apoptotic death of macrophages with concomitant release of IL-1β. 20 Gross amounts of IL-1β are deleterious to the integrity of the intestinal mucosa, which can be reversed by the administration of 1000fold higher amounts of its natural antagonist, IL-1RA. 5, 21 The production of IL-1β and IL-1RA, was similar in CD14-blocked and control animals, despite the finding that CD14-blocked rabbits had on average a 50-fold higher bacterial load. CD14-blockade did not, however, appear to affect the capacity of rabbits to produce another pro-inflammatory cytokine, TNF-α. The levels of this cytokine were almost 20 times higher in the intestinal loops of CD14-blocked rabbits exposed to the invasive Shigella strain, compared to controls. Although CD14-expressing cells such as PMNs and macrophages are able to produce TNF-α, one of the most important sources of TNF-α is the CD14-negative mast cell. This cell type is abundant in the intestinal mucosa and contains preformed TNF-α stored in granules. 22 
CONCLUSIONS
This study shows that modulation of the non-specific immune response, elicited by a local Gram-negative bacterial Blockade of CD14 aggravates experimental shigellosis 445 Fig. 1 . Immunohistochemical stain of bactericidal/permeability-increasing protein (BPI) in the intestinal mucosa of a CD14-blocked rabbit whose intestinal mucosa was exposed to invasive Shigella. Note the strongly stained PMNs in the basal layer of the intestinal mucosa and the PMNs which stain weakly or not at all in the lumenal part of the mucosa, close to the hemorrhagic focus.
infection may ultimately be harmful to the host. Although the activation of professional phagocytic cells by microorganisms may partly contribute to tissue damage, it seems clear that by down-regulating the ability of CD14-expressing cells (monocytes/macrophages, PMNs and possibly endothelial cells) to respond to a bacterial infection, the end result may be enhanced bacterial dissemination, and possibly, secondary to the more widespread bacterial infection, increased tissue destruction.
